3wd9

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
'''Unreleased structure'''
+
{{STRUCTURE_3wd9| PDB=3wd9 | SCENE= }}
 +
===Crystal structure of phosphodiesterase 4B in complex with compound 10f===
 +
{{ABSTRACT_PUBMED_24094436}}
-
The entry 3wd9 is ON HOLD until Paper Publication
+
==Function==
 +
[[http://www.uniprot.org/uniprot/PDE4B_HUMAN PDE4B_HUMAN]] Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents.<ref>PMID:10846163</ref> <ref>PMID:15003452</ref>
-
Authors: Takahashi, M., Hanzawa, H.
+
==About this Structure==
 +
[[3wd9]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3WD9 OCA].
-
Description: Crystal structure of phosphodiesterase 4B in complex with compound 10f
+
==Reference==
 +
<ref group="xtra">PMID:024094436</ref><references group="xtra"/><references/>
 +
[[Category: 3',5'-cyclic-nucleotide phosphodiesterase]]
 +
[[Category: Homo sapiens]]
 +
[[Category: Hanzawa, H.]]
 +
[[Category: Takahashi, M.]]
 +
[[Category: Copd]]
 +
[[Category: Hydrolase-hydrolase inhibitor complex]]
 +
[[Category: Phosphodiesterase]]

Revision as of 06:46, 23 October 2013

Template:STRUCTURE 3wd9

Contents

Crystal structure of phosphodiesterase 4B in complex with compound 10f

Template:ABSTRACT PUBMED 24094436

Function

[PDE4B_HUMAN] Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents.[1] [2]

About this Structure

3wd9 is a 2 chain structure with sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

  • Goto T, Shiina A, Yoshino T, Mizukami K, Hirahara K, Suzuki O, Sogawa Y, Takahashi T, Mikkaichi T, Nakao N, Takahashi M, Hasegawa M, Sasaki S. Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors. Bioorg Med Chem. 2013 Nov 15;21(22):7025-37. doi: 10.1016/j.bmc.2013.09.013. Epub, 2013 Sep 19. PMID:24094436 doi:http://dx.doi.org/10.1016/j.bmc.2013.09.013
  1. ↑ Xu RX, Hassell AM, Vanderwall D, Lambert MH, Holmes WD, Luther MA, Rocque WJ, Milburn MV, Zhao Y, Ke H, Nolte RT. Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science. 2000 Jun 9;288(5472):1822-5. PMID:10846163
  2. ↑ Xu RX, Rocque WJ, Lambert MH, Vanderwall DE, Luther MA, Nolte RT. Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram. J Mol Biol. 2004 Mar 19;337(2):355-65. PMID:15003452 doi:http://dx.doi.org/10.1016/j.jmb.2004.01.040

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/3wd9"
Personal tools